Search

Search Results for "Syfovre"

Pegcetacoplan Extension Study Update thumbnail

Pegcetacoplan Extension Study Update

Jeffrey S. Heier, MD

Pegcetacoplan in the Trials and the Real-World thumbnail

Pegcetacoplan in the Trials and the Real-World

David A. Eichenbaum, MD

36 Months of GA Therapy with Pegcetacoplan thumbnail

36 Months of GA Therapy with Pegcetacoplan

Dilsher S. Dhoot, MD

A Look at Three-Year Data for Pegcetacoplan thumbnail

A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

Pegcetacoplan in the Real World: Year 1 thumbnail

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Wet AMD Incidence with GA Therapy thumbnail

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

GA Therapy After the Newest DERBY/OAKS Data thumbnail

GA Therapy After the Newest DERBY/OAKS Data

Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD

Using AI to Track GA Treatment Response thumbnail

Using AI to Track GA Treatment Response

Ursula M. Schmidt-Erfurth, MD

What You Need to Know About Pegcetacoplan Injection thumbnail

What You Need to Know About Pegcetacoplan Injection

Joseph Allen, OD, FAAO, Dipl ABO

When to Treat with Pegcetacoplan thumbnail

When to Treat with Pegcetacoplan

Roger A. Goldberg, MD, MBA

The Era of Geographic Atrophy Treatment Begins

Allen C. Ho, MD; and Robert L. Avery, MD

ASRS ’23: Pegcetacoplan Extension Study, and Comparison of Pegcetacoplan and Avacincaptad Pegol

Nathan C. Steinle, MD; and Paul Hahn, MD, PhD

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

Katherine Talcott, MD; and Sunir Garg, MD

Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy

Esther Kim, MD; John W. Kitchens, MD; and Scott Walter, MD

Treating Geographic Atrophy (GA) In Your Practice

Esther Kim, MD; John W. Kitchens, MD; and Scott Walter, MD

GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?

John Kitchens, MD; Saradha Chexal, MD; and Geeta Lalwani, MD

View More